[
  {
    "ts": "2025-11-07T13:30:00+00:00",
    "headline": "FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma",
    "summary": "Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug Administration (FDA) approval of a new indication for DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) co-formulated with ENHANZE®, as single agent treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). DARZALEX Faspro® is the first and only approved treatment for HR-SMM, enabling earlier intervention before the disease progresses to active multi",
    "url": "https://finance.yahoo.com/news/fda-approved-darzalex-faspro-adult-133000949.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "3fd89802-7e65-3470-bce4-893b763978cc",
      "content": {
        "id": "3fd89802-7e65-3470-bce4-893b763978cc",
        "contentType": "STORY",
        "title": "FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma",
        "description": "",
        "summary": "Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug Administration (FDA) approval of a new indication for DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) co-formulated with ENHANZE®, as single agent treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). DARZALEX Faspro® is the first and only approved treatment for HR-SMM, enabling earlier intervention before the disease progresses to active multi",
        "pubDate": "2025-11-07T13:30:00Z",
        "displayTime": "2025-11-07T13:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/c2d10463941059496c22a9967916bfb1",
          "originalWidth": 400,
          "originalHeight": 167,
          "caption": "Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.) (PRNewsfoto/Halozyme Therapeutics, Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g75kczZcd5MaZJYqyjNiSg--~B/aD0xNjc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c2d10463941059496c22a9967916bfb1.cf.webp",
              "width": 400,
              "height": 167,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/So_e66wwLJmH4i1xsBBqvA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c2d10463941059496c22a9967916bfb1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-approved-darzalex-faspro-adult-133000949.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-approved-darzalex-faspro-adult-133000949.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HALO"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]